uz
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Kanalga Telegramโ€™da oโ€˜tish

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Ko'proq ko'rsatish

๐Ÿ“ˆ Telegram kanali ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ analitikasi

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 339 obunachidan iborat bo'lib, Tibbiyot toifasida 1 928-o'rinni va Saudiya Arabistoni mintaqasida 5 694-o'rinni egallagan.

๐Ÿ“Š Auditoriya koโ€˜rsatkichlari va dinamika

ะฝะตะฒั–ะดะพะผะพ sanasidan buyon loyiha tez oโ€˜sib, 13 339 obunachiga ega boโ€˜ldi.

28 Iyun, 2026 dagi oxirgi maโ€™lumotlarga koโ€˜ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 196 ga, soโ€˜nggi 24 soatda esa -18 ga oโ€˜zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya oโ€˜rtacha 27.91% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 9.87% ini tashkil etuvchi reaksiyalarni toโ€˜playdi.
  • Post qamrovi: Har bir post oโ€˜rtacha 3 727 marta koโ€˜riladi; birinchi sutkada odatda 1 318 ta koโ€˜rish yigโ€˜iladi.
  • Reaksiyalar va oโ€˜zaro taโ€™sir: Auditoriya faol: har bir postga oโ€˜rtacha 36 ta reaksiya keladi.
  • Tematik yoโ€˜nalishlar: Kontent ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ kabi asosiy mavzularga jamlangan.

๐Ÿ“ Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโ€™riflaydi:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Yuqori yangilanish chastotasi (oxirgi maโ€™lumot 29 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโ€˜lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโ€™sir nuqtasiga aylantirishini koโ€˜rsatadi.

13 339
Obunachilar
-1824 soatlar
+2847 kunlar
+19630 kunlar
Postlar arxiv
ู…ุฑุญุจุง ุงู†ูŠ ุทุงู„ุจุฉ ุตูŠุฏู„ุฉ ุฌุงู…ุนู‡ ุงู„ู…ุดุฑู‚ ุนู†ุฏูŠ ุจุญุซ ูŠุฎุต ุจุฎุงุฎุงุช ุงู„ุฑุจูˆ ูˆ COPD ู…ู…ูƒู† ุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ูˆ ุงู‡ู…ุดูŠ ุฑู‚ู… collaborator code :3 ูˆ ุดูƒุฑุงู‹ https://forms.gle/hFujpBaFvBNf3kNF6

An intramuscular agent, is approved for second line therapy of postmenopausal patients with hormone receptor-positive breast cancer either alone or in combination with targeted therapy? A) Tamoxifen B) Raloxifene C) Toremifene D) pertuzumab E) Fulvestrant ุจู…ุญุงุถุฑุฉ ุงู„ breast cancer ูู‚ุท ุฏูˆุงุก ูˆุงุญุฏ ู…ุฐูƒูˆุฑ ุงู†ู‡ ู†ู†ุทูŠู‡ im ูŠุนู†ูŠ ุจุฏูˆู† ู…ุง ุชูƒู…ู„ ุงู„ุณุคุงู„ ุชุฎุชุงุฑ ูˆุงู†ุช ู…ุบู…ุถ ูˆูƒู„ุงู… ุงู„ุณุคุงู„ ู†ุตุง ู…ู† ุงู„ู…ู„ุฒู…ุฉ ู…ุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู…ูŠุฒุฉ ู…ุฌุฑุฏ ู…ุนู„ูˆู…ุฉ ุฏุฑุฎูŠุฉ ูˆุฒุงุฑูŠ 25 ุฏูˆุฑ 1 #Breast_Cancer

HER2 over expressing MBC, what is the preferred First line therapy?
Anonymous voting

A patient with HER2-positive MBC was initially treated with a combination of pertuzumab, trastuzumab, and a taxane. After months, her disease progressed. Which of the following treatments is most appropriate as second-line HER2- targeted therapy?
Anonymous voting

ุงู…ุณูƒูŠูˆ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ู…ูˆุงุฏ ุงู„ู†ุธุฑูŠ ุนู„ุงุฌูŠุงุช ุงุฏูุงู†ุณ ุงู‚ุชุตุงุฏูŠุงุช. TDM DDS ุงู„ุจุงูŠูˆุชูƒู†ูˆู„ุฌูŠ ู…/// ู…ู† ู†ู†ุฒู„ ุดูŠ ูŠู†ุถุงู ุน ุงู„ู‚ูˆุงุฆู… ุญุณุจ ูƒู„ ู…ุงุฏุฉ๐Ÿ‘Œ

45-year-old patient with HER2+ breast cancer received neoadjuvant chemotherapy plus trastuzumab and pertuzumab. At surgery, a residual disease was found. Which agent is most appropriate for adjuvant therapy in this condition ?
Anonymous voting

Salma is a 35 years old women presented to gynecologist seeking for strategies for breast cancer prevention because of her positive family history with BRCA 1 and BRCA2 gene test; The best treatment for risk reduction include:
Anonymous voting

Which genetic mutations significantly incrcase the lifetime risk of breast cancer? a- BRCA1 and BRCA2 b- TPS3 and EGFR c- KRAS and NRAS d- ATM and CHEK2 e- BRCA3 and PALB2 ุฏูˆุฑ ุงูˆู„ 2024 ุทุจุนุง ู‡ุงูŠ ุงู„ุงุณุฆู„ุฉ ุชุฎุต ุงูˆู„ ู…ุญุงุถุฑุฉ ู†ุฒู„ุชู‡ุง ุงู„ูƒู… ุงู„ู…ุญุงุถุฑุฉ ุงู„ุฌุงูŠุฉ ุนู„ุงุฌุงุช ุงู„ breast cancer ุณุคุงู„ ุณู‡ู„ ูˆุญุชู‰ ู…ุชู†ุณูˆู† Breast Cancer ู‡ูˆ BR CA #Breast_Cancer

Drug used to prevent Breast cancer. Which drug increased incidence of endometrial cancer a- Exemestane b- anastrozole c- tamoxifen d- raloxifene e- Letrozole ูˆุฒุงุฑูŠ ุฏูˆุฑ ุงูˆู„ 2024 ุงู„ุญู„ ู…ู† ุงู„ุตูˆุฑุฉ ๐Ÿซ† #Breast_Cancer

A 41 years old woman with a positive family history of breast cancer. What is the treatment of choice to reduce her risk breast cancer risk?
Anonymous voting

A 66 years old woman is suffering from low mineral bone density and strong family history of breast cancer. What would be the best protective agent? #Breast_Cancer
Anonymous voting

ุทู„ุงุจ ุงู„ุฎุงู…ุณุฉ ุงู†ุง ุงู† ุดุงุก ุงู„ู„ู‡ ุงูƒู…ู„ ุงู„ูƒุงู†ุณุฑ ูˆุงุจุฏูŠ ุจุงู„ู†ูุณูŠุฉ ู…ู†ุง ู„ุฐุงูƒ ุงู„ูˆู‚ุช ู‡ูˆุงูŠ ุทู„ุงุจ ุชุฑูŠุฏ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ู„ู„ู†ูุณูŠุฉ ู ุงู† ุดุงุก ุงู„ู„ู‡ ุงุซู†ุงุก ุดุฑุญูŠ ู„ู„ูƒุงู†ุณุฑ ุฑุญ ุชู†ุฒู„ ุจู‚ูŠุฉ ุงู„ู…ูˆุงุถูŠุน ุจุดูƒู„ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ุชุจุงุนุง